---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-025893"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2025-12-03T23:59:59+00:00"
generated_at: "2026-05-16T15:16:33.313874+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# bioAffinity to present CyPath Lung data showing Stage 1A detection in challenging cases at ACS NLCRT Dec 8

## Summary
- CyPath Lung identified Stage 1A lung cancer in three patients with atypical presentations.
- Poster session at American Cancer Society National Lung Cancer Roundtable on Dec 8, 2025, 2:35-3:15 p.m. ET.
- Chief Medical Officer Gordon Downie presenting cases from Titus Regional Hospital Lung Nodule Clinic.
- Test uses flow cytometry and AI on sputum; prior study showed 92% sensitivity and 87% specificity.

## SEC filing metadata
- accession: 0001493152-25-025893
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2025-12-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315225025893/0001493152-25-025893-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315225025893/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-025893
- JSON: https://secwatch.observer/filing/0001493152-25-025893.json
- Plain text: https://secwatch.observer/filing/0001493152-25-025893.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.